WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2018015340) BISPECIFIC ANTIBODY-LIKE BINDING PROTEINS SPECIFICALLY BINDING TO CD3 AND CD123
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.:    WO/2018/015340    International Application No.:    PCT/EP2017/068020
Publication Date: 25.01.2018 International Filing Date: 17.07.2017
IPC:
C07K 16/28 (2006.01), A61K 39/395 (2006.01), A61K 39/00 (2006.01)
Applicants: SANOFI [FR/FR]; 54 rue La Boétie 75008 PARIS (FR)
Inventors: ALBRECHT, Jana; (DE).
BEIL, Christian; (DE).
BENINGA, Jochen; (DE).
KROLL, Katja; (DE).
LANGE, Christian; (DE).
LEUSCHNER, Wulf Dirk; (DE).
RAO, Ercole; (DE).
SCHNEIDER, Marion; (DE).
WONEROW, Peter; (DE).
GUERIF, Stéphane; (FR)
Agent: TINEL, Marie-Line; (FR)
Priority Data:
16305923.1 18.07.2016 EP
Title (EN) BISPECIFIC ANTIBODY-LIKE BINDING PROTEINS SPECIFICALLY BINDING TO CD3 AND CD123
(FR) PROTÉINES DE LIAISON BISPÉCIFIQUES DE TYPE ANTICORPS SE LIANT SPÉCIFIQUEMENT À CD3 ET CD123
Abstract: front page image
(EN)The present invention concerns antibody-like binding protein specifically binding to CD3 and CD123. The invention also relates to pharmaceutical compositions comprising said antibody-like binding protein and the use of said pharmaceutical compositions and antibody-like binding protein to treat cancer. The invention further relates to isolated nucleic acids, vectors and host cells comprising a sequence encoding said antibody-like binding protein.
(FR)La présente invention concerne une protéine de liaison de type anticorps se liant spécifiquement à CD3 et à CD123. L'invention concerne également des compositions pharmaceutiques comprenant ladite protéine de liaison de type anticorps et l'utilisation desdites compositions pharmaceutiques et de ladite protéine de liaison de type anticorps pour traiter le cancer. L'invention concerne en outre des acides nucléiques isolés, des vecteurs et des cellules hôtes comprenant une séquence codant ladite protéine de liaison de type anticorps.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)